TD Cowen analyst Dan Brennan lowered the price target on Danaher (NYSE: DHR) to $240.00 (from $245.00) while maintaining a Buy rating.

The analyst commented, "DHR's stock gave back gains post a mixed 1Q (missed organic given flu; beat EPS) & call (S&P sell off a factor). Many investors we meet want clear signs to support the 2H ramp (not just for DHR but for Tools; a reason for negative sentiment). We feel better about DHR's 2H now as mgmt on the call pointed to several signs of improving demand including bioproduction eqpt, biopharma R&D, and China."